About us
TargaGenix was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.
- Website
-
https://www.targagenixinc.com
External link for TargaGenix
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Stony Brook, New York
- Type
- Privately Held
- Founded
- 2013
Locations
-
Get directions
25 Health Sciences Dr Ste 208
Stony Brook, New York 11790, US